key: cord-1035560-v9ye2a2w authors: Díaz-Salinas, Marco A.; Li, Qi; Ejemel, Monir; Yurkovetskiy, Leonid; Luban, Jeremy; Shen, Kuang; Wang, Yang; Munro, James B. title: Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike date: 2021-11-09 journal: bioRxiv DOI: 10.1101/2021.10.29.466470 sha: ce80da5f8c134acf6b683cae0458e66e528ea509 doc_id: 1035560 cord_uid: v9ye2a2w Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects cells through binding to angiotensin-converting enzyme 2 (ACE2). This interaction is mediated by the receptor-binding domain (RBD) of the viral spike (S) glycoprotein. Structural and dynamic data have shown that S can adopt multiple conformations, which controls the exposure of the ACE2-binding site in the RBD. Here, using single-molecule Förster resonance energy transfer (smFRET) imaging we report the effects of ACE2 and antibody binding on the conformational dynamics of S from the Wuhan-1 strain and the B.1 variant (D614G). We find that D614G modulates the energetics of the RBD position in a manner similar to ACE2 binding. We also find that antibodies that target diverse epitopes, including those distal to the RBD, stabilize the RBD in a position competent for ACE2 binding. Parallel solution-based binding experiments using fluorescence correlation spectroscopy (FCS) indicate antibody-mediated enhancement of ACE2 binding. These findings inform on novel strategies for therapeutic antibody cocktails. These structural and biophysical data suggest that modulating the conformational 51 equilibrium of the RBD of S might be a determinant of SARS-CoV-2 infectivity and 52 neutralization sensitivity. By the summer of 2020, the SARS-CoV-2 S variant D614G (strain B.1) 53 had supplanted the ancestral virus (strain Wuhan-1) worldwide, and structural analysis showed 54 that D614G disrupts an interprotomer contact (19) . This disruption results in a shift in the RBD 55 conformation toward the up position, which is competent for ACE2 binding, consistent with 56 increases in in vitro virus-cell binding mediated by ACE2 and infectivity (16, 20) . At the same 57 time, the enhanced exposure of the RBM in the D614G variant led to increased sensitivity to 58 neutralizing antibodies (21). Furthermore, the RBD showed stabilization in the up position, as 59 well as an intermediate conformation, upon treatment with a neutralizing S2 stalk-directed 60 antibody (22, 23) . 61 Here we report on the conformational dynamics of SARS-CoV-2 S in the absence or 62 presence of ligands visualized using an smFRET imaging assay (Fig. 1A) . Our results indicate 63 that ACE2 binding is controlled by the intrinsic conformational dynamics of the RBD, with ACE2 64 capturing the intrinsically accessible up conformation rather than inducing a conformational 65 change. We find that antibodies that target diverse epitopes-including epitopes in the NTD and 66 in the S2 stalk, which are distal to the RBD-tend to shift the RBD equilibrium on the D614 spike 67 toward the up conformation, enhancing ACE2 binding. The D614G spike existed in an 68 equilibrium where the RBD favors the up conformation prior to antibody binding. Nonetheless, 69 antibodies that target the S2 stalk further promoted the RBD-up conformation on the D614G 70 spike. We thus observe long-range allosteric modulation of the RBD equilibrium, which in turn 71 regulates exposure of the ACE2-binding site. Inducing exposure of key neutralizing epitopes with 72 antibodies will inform the design of novel therapeutic cocktails (24-26). 73 74 Results 75 Tagged SARS-CoV-2 S spike maintains a native conformation 76 With the aim of visualizing the conformational dynamics in real-time of SARS-CoV-2 S, 77 we developed an smFRET imaging assay. We specifically sought to probe the movement of the 78 RBD between the up and down positions. To this end, guided by the available structural data (10, 79 11) (Fig. 1A) , we inserted the 8-amino-acid A4 peptide into the spike ectodomain (SDTM) within 80 loops located between the β7-β8 strands in the NTD at position 161, and between helix α1 and 81 strand β1 in the RBD at position 345 (Fig. 1B) . Fluorophores were then enzymatically attached to 82 the A4 tags through incubation with AcpS (27). This approach was chosen because it was 83 previously used for conformational dynamics studies of S, as well as the spike proteins from HIV-84 1 and Ebola (18, [28] [29] [30] . Structural analysis indicated an increase in the distance between the 85 attachment sites of LD550 and LD650 fluorophores after the RBD transitions from the down to 86 the up conformation, suggesting that this labeling strategy would allow us to visualize this 87 dynamic event (Fig. 1A) (18). 88 Before proceeding to smFRET imaging, we first sought to validate the structure and 89 antigenicity of the 161/345A4-tagged SΔTM trimer. Homo-trimers with either D614 or D614G 90 were validated through two different approaches: (1) evaluation of their binding to ACE2 and, (2) 91 evaluation of their antigenic characteristics compared with untagged SΔTM (Fig. S1A-B) . We 92 developed a fluorescence correlation spectroscopy (FCS) assay to evaluate ACE2 binding to A4-93 tagged SΔTM trimers in solution ( Fig. 2A) . For this assay, purified ACE2 ( Fig. S1C ) was 94 conjugated to the Cy5 fluorophore (Fig. S1D ). Cy5-ACE2 was incubated with varying 95 concentrations of either tagged or untagged SΔTM and the timescale of diffusion was measured 96 using FCS. The FCS data were fit to a model of two diffusing species (31) (Fig. 2B) (36), as well as the stalk-targeting antibodies 1A9 (37) and 2G12 (38) (Fig. S2A ). A4-tagged 108 SΔTM homo-trimers maintained more than 50% of antibody binding compared to untagged 109 SΔTM (Fig. S2B) consistent with ACE2 promoting the RBD-up conformation. HMM analysis also indicated a 130 reduction in the overall dynamics upon ACE2 binding, as indicated by the transition density plots 131 (TDPs; Fig. 3A -B), which display the relative frequencies of transitions between the high-and 132 low-FRET states. The rates of transition were determined through maximum likelihood 133 estimation. This analysis indicated that transition from the high-to the low-FRET state occurred 134 at k-1=2.6±0.2 sec -1 , whereas the low-to high-FRET transition occurred at k1=3.8±0.2 sec -1 . ACE2 135 binding had minimal effect on the high-to low-FRET transition (k-1=2.2±0.2 sec -1 ), but reduced 136 the low-to high-FRET transition to k1=1.3±0.1 sec -1 (Fig. 3D ). This analysis thus specified that 137 the effect of ACE2 binding is to capture and stabilize the up conformation (low-FRET state) and 138 reduce transitions to the down conformation (high-FRET state). ACE2 binding does not 139 significantly affect the stability of the down conformation, nor induce transitions to the up 140 conformation. 141 We next sought to determine the effect of the D614G mutation on the conformational 142 dynamics of SDTM. We observed the same two FRET states for SDTM D614G as for the 143 ancestral D614 spike (Fig. 3E) . However, the unbound SDTM D614G displayed greater 144 occupancy in the low-FRET state (60.9±2.5%), and the overall level of dynamics was reduced as 145 compared to D614 (Fig. 3E-G) . The rate constants, k-1 and k1, were reduced to 2.0±0.2 sec -1 and 146 1.6±0.2 sec -1 , respectively (Fig. 3H ). ACE2 binding further increased the low-FRET occupancy to 147 74.5±2.2% and reduced the overall level of dynamics shown in the TDPs (Fig. 3F ). As seen for 148 D614, ACE2 binding had minimal effect on the rate of transition from the high-to the low-FRET 149 state (k-1=2.0±0.4 sec -1 ) but reduced the rate of transition from the low-to the high-FRET state to 150 k1=0.7±0.1 sec -1 (Fig. 3H) . Thus, consistent with structural studies (16, 19) , the D614G mutation 151 shifted the conformational equilibrium in favor of the RBD-up conformation. Also, here again, 152 ACE2 binding stabilized the RBD-up conformation without affecting the energetics of the RBD-153 down conformation. 154 155 RBD-targeting antibodies promote the RBD-up conformation of S D614 156 Numerous neutralizing monoclonal antibodies (mAbs) targeting SARS-CoV-2 S have 157 been identified (39). However, their mechanisms of action have only been partially described, 158 especially for mAbs that target epitopes outside of the RBD. We first sought to use our smFRET 159 imaging approach to explore the effect of RBD-directed mAbs on SDTM dynamics for both the 160 D614 and D614G variants. We chose neutralizing RBD-directed mAbs from different classified 161 groups according to the epitope targeted (40): (1) MAb362 (isoforms IgG1 and IgA1) that directly 162 targets the RBM(32); (2) REGN10987, which binds an epitope located on the side of the RBD, 163 blocking ACE2 binding without directly interacting with the RBM (33); and S309 and CR3022 164 that bind the RBD but do not compete with ACE2 binding (34, 35). Imaging of SDTM D614 pre-165 incubated with each of the above mAbs revealed a predominant low-FRET state associated with 166 the RBD in the up conformation ( Fig. S3 , left, and Table S2 ). In all cases, the mAbs stabilized the 167 low-FRET state as compared to the unbound SDTM, although none to the extent seen for ACE2 168 (Fig. 4A ). As observed during ACE2 binding, the mAbs generally induced a larger effect on the 169 rate of transition from the low-to the high-FRET state (k1), with a minor effect on the high-to 170 low-FRET transition (k-1; Fig. 4B ). In contrast, none of the mAbs stabilized the low-FRET state 171 for SDTM D614G to a significant extent (Figs. 4A, S3 and Table S3 ), suggesting that the effect of 172 the D614G mutation is sufficient to enable mAb binding without further conformational changes. 173 174 NTD-and stalk-targeting mAbs allosterically modulate the RBD position 175 Several mAbs have been identified that target epitopes outside of the RBD. Some of 176 which bind the NTD and are potently neutralizing (36, 41-43). We therefore explored the 177 conformational dynamics of both SDTM D614 and D614G pre-treated with the NTD-targeting 178 mAb 4A8 (36), and with the S2 stalk-directed mAbs 1A9 (37) and 2G12 (38). 4A8 treatment of 179 SDTM D614 stabilized the low-FRET state to a comparable extent as seen for the RBD-targeted 180 mAbs (Figs. 4C, S3, and Table S2 ). The change in transition rates also followed a similar trend as 181 seen for RBD-targeted mAbs with the low-to high-FRET (k1) transition being reduced, with a 182 minor effect on the high-to low-FRET transition (k-1; Figs. 4D, S3, and Table S2 ). The stalk-183 directed mAbs 1A9 and 2G12 also stabilized the low-FRET state (Figs. 4C, S3, and Table S2), 184 although kinetic analysis revealed a modulation of the dynamics that was distinct from the S1-185 targeted mAbs. Here, the rates of low-to high-FRET transition were reduced, while the rates of 186 high-to low-FRET transition were increased (Fig. 4D ). For SDTM D614G, 4A8 had only a minor 187 effect on low-FRET stability or kinetics, again suggesting that the mAb binds without affecting 188 the conformational equilibrium. However, the stalk-targeting 1A9 and 2G12 mAbs stabilized low 189 FRET and induced increases in the rates of transition out of high FRET (Fig. 4A , S3, and Table 190 S3). These data indicate that the S2 stalk-targeting mAbs studied here allosterically induce 191 transition of the RDB to the up conformation on both the D614 and D614G spikes. In contrast, the 192 RBD-and NTD-targeting mAbs studied here capture the up conformation without actively 193 inducing a conformational change, similar to the effects of ACE2 on the RBD conformation. 194 195 Stalk-targeting mAbs allosterically enhance ACE2 binding 196 We next asked if stabilization of the RBD-up conformation by NTD-and stalk-targeted 197 mAbs would increase ACE2 binding. We therefore applied our FCS assay for ACE2 binding after 198 pre-treating SDTM D614 or D614G with mAbs (Material and Methods conformation without affecting the energetics of the down conformation (Fig. 6A ). This analysis 227 of S dynamics specifies that ACE2 binding to S does not induce a conformational change in S, 228 but rather occurs through the capture of a pre-existing conformation. 229 As ACE2 binding is an essential step during SARS-CoV-2 entry, our interpretation 230 implicates the intrinsic dynamics of S in controlling the rate or efficiency of membrane fusion 231 during virus entry. the RBD-up to -down transition indicates an increase in the activation energy, which is mainly 245 explained by an increase in thermodynamic stability of the RBD-up conformation (Fig. 6A ). 246 ACE2 binding to S D614G had an additive effect on the RBD position, pushing the equilibrium 247 further toward the up conformation than either ACE2 binding or the D614G mutation did 248 independently. Thus, the D614G mutation permits further stabilization of an intermediate 249 conformation captured by ACE2 binding. Here again, ACE2 binding functioned by specifically 250 increasing the thermodynamic stability of the RBD-up conformation. Residue D614 is distal to 251 the RBD and forms a salt bridge with K854 in the fusion-peptide proximal region, which is lost 252 with the D614G mutation (17, 19, 46) . Our analysis shows that the D614-K854 electrostatic 253 interaction had a destabilizing effect on the thermodynamics of the RBD-up conformation. The 254 similar impacts of D614G and ACE2 binding on the S energetic landscape implies that the 255 mutation provides a fitness advantage by mimicking the effects of receptor binding. Such a long-256 range allosteric connection between the receptor-binding domain and the region surrounding the 257 fusion peptide has been reported for the influenza hemagglutinin and the Ebola virus envelope 258 glycoprotein (47-49), suggestive of a common mechanistic connection between receptor binding 259 and triggering movement of the fusion peptide (or fusion loop) among class-I viral fusion 260 proteins. 261 We find that mAbs that target S1 of the D614 spike, including the RBD and NTD, have a 262 similar impact on conformational dynamics as ACE2, with the predominant effect being the 263 reduction in the rate of transition to the down conformation. The overall minimal effect on the 264 rate of transition to the up conformation is again consistent with thermodynamic stabilization and 265 the capture of a pre-existing S conformation (Fig. 6B) . mAb S309 had a notably modest effect on 266 the stability of the up conformation, consistent with structural data demonstrating that it binds to 267 the RBD in either the up or down positions (34). Overall, RBD-and NTD-targeting mAbs had 268 minimal effect on the conformation of the D614G spike. The exception was mAb S309, which 269 modestly destabilized the up conformation, shifting the equilibrium to approximately that seen for 270 the D614 spike bound to S309. As S309 does not prevent ACE2 binding, its mechanism of broad 271 neutralization remains unclear (34, 50). However, its modulation of the RBD position likely plays 272 some role and may impact downstream conformational changes related to membrane fusion. 273 Our kinetic analyses have shown that the S1-targeted ligands considered here capture the 274 up conformation. In contrast, the S2-targeted mAbs considered here induce conformational 275 changes in the RBD by reducing the activation energy for transition into the up conformation, 276 while also stabilizing the up conformation (Fig. 6C ). Cryo-electron tomography of SARS-CoV-2 277 virions has revealed the presence of three flexible hinges within the S stalk: the hip, knee, and 278 ankle. These hinges connect the head, and the upper and lower legs of S and confer flexibility on 279 the spikes (51, 52). Our smFRET data demonstrate that stalk-targeted mAbs 1A9 and 2G12 280 allosterically modulate the position of the RBD, enhancing ACE2 binding. mAb 1A9, which 281 neutralizes SARS-CoV, binds an epitope on S in the upper leg of the stalk near the hip and 282 upstream of the heptad repeat helix 2 (53). High sequence conservation in the 1A9 epitope 283 suggests a similar binding site in SARS-CoV-2 S and mode of action in preventing viral 284 membrane fusion (37). The stalk epitope recognized by mAb 2G12, which does not neutralize 285 SARS-CoV-2, is located near the hip and is comprised entirely of glycans (38) (Fig. S2A) . Taken 286 together, our data on 1A9 and 2G12 implicate the hip hinge as a critical center for allosteric 287 control of the RBD position. Further support for the existence of allosteric centers in S2 came 288 from other smFRET analyses of mAb CV3-25 (54), which binds an epitope in the upper leg of the 289 stalk near the knee (23). CV3-25 was also found to promote the RBD-up conformation (22, 23) . 290 Further studies are necessary to determine whether mAbs that target the lower leg and ankle hinge 291 also exert allosteric control of the RBD. 292 The use of therapeutic mAb cocktails is a promising strategy, which has been explored for 293 the treatment and prevention of Ebola virus disease (55 Plasmids and site-directed mutagenesis 337 The mammalian codon-optimized gene coding SARS-CoV-2 (Wuhan-Hu-1 strain, 338 GenBank ID: MN908947.3) glycoprotein ectodomain (SDTM) (residues Q14-K1211) with 339 SGAG substitution at the furin cleavage site (R682 to R685), and proline substitutions at K986 340 and V987, was synthesized by GenScript ® (Piscataway, NJ, USA) and inserted into pcDNA3.1(-). 341 A C-terminal T4 fibritin foldon trimerization motif, a TEV protease cleavage site, and a His-tag 342 were synthesized downstream of the SARS-CoV-2 SDTM (Fig. 1B) . Insertion of A4 peptide 343 (DSLDMLEW) at amino acid position 161 in SARS-CoV-2 SDTM was done through overlap-344 extension PCR(60). Primers 2S-Age-I-F, 2S-161A4-2, 2S-161A4-3, and 2S-ApaI-R (Table S1) 345 were used in the PCR reactions to obtain a final product bearing the 161A4 insertion, which was 346 cloned into SDTM using the AgeI and ApaI restriction sites. A similar strategy was performed for 347 the A4 insertion at position 345 of SDTM using 2S-XhoI-F, 2S-345A4-2, 2S-345A4-3, and 2S-348 ApaI-R primers (Table S1) in the PCR reactions. The final PCR product bearing the 345A4 349 insertion was cloned into SDTM using the XhoI and ApaI restriction sites. To generate the 350 161/345A4 double-tagged construct, the 345A4 insertion was subcloned into the 161A4 construct 351 through XhoI and ApaI digestion. Mutagenic PCR to obtain the D614G amino acid change into 352 both untagged and 161/345A4-tagged SDTM constructs was done using the primers 353 S2_D614_Q5-F and S2_D614_Q5-R (Table S1) USA) (Fig. S1 ). Double 161/345A4-tagged SDTM homo-trimers for functional assays were 373 extracted from ExpiCHO-S ™ cells at 6 days pot-transfection with a non-denaturing lysis buffer 374 (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 10% (v/v) glycerol, 1% (v/v) Triton ™ X-100, 2 mg/ml 375 aprotinin, 1 mg/ml leupeptin, and 1 mg/ml pepstatin A (Sigma-Aldrich ® , St. Louis, MO, USA)). 376 After 20 minutes of centrifugation at 4000 xg, the soluble fraction was diluted with two volumes 377 of the same buffer without Triton ™ X-100. These extracts were then passed through a 0.45 mm 378 polyethersulfone filter unit (Nalgene ™ , Thermo Fisher Scientific, Waltham, MA, USA), and the 379 tagged SDTM was purified by affinity chromatography using Ni-NTA agarose beads 380 (Invitrogen ™ , Waltham, MA, USA) and size exclusion chromatography as described above. 381 382 A plasmid encoding soluble monomeric ACE2 with a C-terminal 6x-His tag was 383 transfected into ExpiCHO-S ™ cells as described above. Supernatant containing ACE2 was 384 harvested six days post-transfection, dialyzed at 4 ºC into 20 mM Tris-HCl pH 8.0, 500 mM NaCl 385 and 10% (v/v) glycerol buffer, using a 10 kDa MWCO dialysis membrane (Spectrum ® Repligen, 386 Waltham, MA, USA). For ACE2 purification, the dialyzed supernatant was supplemented with 20 387 mM imidazole pH 8.0 before purification as described above for SDTM. Purified protein 388 concentrations were estimated by UV absorbance at 280 nm and Bradford assay (Thermo Fisher 389 Scientific, Waltham, MA, USA). SDTM concentration was also estimated by densitometric 390 analysis of protein bands on immunoblots with the monoclonal antibody 1A9 as described below, 391 and using ImageJ software v1.52q (NIH, USA were made for 10 sec each at room temperature for each experimental condition. To obtain the 474 fractions of unbound and bound (f) ACE2 after incubation with SΔTM, normalized 475 autocorrelation curves were fit to a model of the diffusion of two species in a three-dimensional 476 Gaussian confocal volume(67, 68), and ti is the diffusion time for bound or unbound ACE2 and s is the structure factor that 481 parameterizes the dimensions of the confocal volume. To determine tunbound FCS data was 482 obtained for ACE2 in the absence of SDTM and fit to a model of a single diffusing species (f = 0). 483 This value was then fixed during fitting of the FCS data obtained after incubation of ACE2 with 484 SDTM, so that only tbound and f were allowed to vary. ACE2 binding was expressed as the average 485 bound fraction (f) at each SDTM concentration normalized either to the fraction bound at the 486 highest SDTM concentration (Fig. 2C) , or to the fraction bound in the absence of antibodies (Fig. 487 5). All fitting was performed with a non-linear least-squares algorithm in MATLAB (The 488 MathWorks, Waltham, MA, USA). Dissociation constants (KD) were determined using GraphPad 489 Prism version 9.2.0 (GraphPad Software, San Diego, CA, USA Correlation and statistical analysis 497 Data sets subjected to statistical analysis were first tested for normality using GraphPad 498 Prism version 9.2.0 (GraphPad Software, San Diego, CA, USA). Where indicated, statistical 499 significances were evaluated through either two-tailed parametric (unpaired t-test with Welch's 500 correction) or nonparametric (unpaired Mann-Whitney) tests. Both tests were performed with 501 95% confidence levels and P values <0.05 were considered significant. Significance values are 502 indicated as *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Two-tailed nonparametric 503 Spearman test with 95% confidence was performed to evaluate the correlation level between the 504 occupancy of SDTM in the open conformation due to allosteric antibody binding and ACE2 505 binding (Figs. 4 and 5) . The correlation level between the above variables was determined 506 according to established criteria(69) regarding Spearman coefficients (rs) rank values as follows: 507 0.00-0.10 = "negligible", 0.10-0.39 = "weak", 0.40-0.69 = "moderate", 0.70-0.89 = "strong", and 508 0.90-1.00 = "very strong" correlation. A pneumonia outbreak associated with a new coronavirus of probable bat 515 origin Safety and Efficacy of COVID-19 Vaccines: A 517 Systematic Review and Meta-Analysis of Different Vaccines at Phase 3 A Comprehensive Overview on COVID-19: 520 Future Perspectives Functional assessment of cell entry and receptor usage for 522 SARS-CoV-2 and other lineage B betacoronaviruses Structural basis for the recognition of 524 SARS-CoV-2 by full-length human ACE2 526 Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor Structural 529 basis of receptor recognition by SARS-CoV-2 CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven 533 Structural and Functional Basis of SARS-CoV-2 Entry by Using 536 Human ACE2 Antigenicity of the SARS-CoV-2 Spike Glycoprotein Distinct conformational states of SARS-CoV-2 spike protein Structure of SARS-CoV-2 spike protein Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein 557 Variant Cryo-EM Structures of SARS-CoV-2 Spike without and with 562 ACE2 Reveal a pH-Dependent Switch to Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles Structural impact on SARS-CoV-2 spike protein 571 by D614G substitution Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases 579 Infectivity of the COVID-19 Virus D614G Spike Mutation Increases SARS 584 CoV-2 Susceptibility to Neutralization Live imaging of SARS-CoV-2 infection in mice reveals that 590 neutralizing antibodies require Fc function for optimal efficacy Emerging antibody-based therapeutics against SARS-CoV-2 during the global 597 pandemic Neutralizing Antibody Therapeutics for COVID-19 Tackling COVID-19 with neutralizing 601 monoclonal antibodies An Eight Residue Fragment of 603 an Acyl Carrier Protein Suffices for Post-Translational Introduction of Fluorescent Pantetheinyl 604 Arms in Protein Modification in vitro and in vivo An Asymmetric Opening of HIV-1 Envelope Mediates Antibody-609 Dependent Cellular Cytotoxicity Real-Time Analysis of Individual Ebola Virus Glycoproteins Reveals 612 Entry-Relevant Conformational Dynamics Principles of Fluorescence Spectroscopy A cross-reactive human IgA monoclonal 621 antibody blocks SARS-CoV-2 spike-ACE2 interaction 628 Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. 629 Science Cross-neutralization of SARS-CoV-2 by a human 634 monoclonal SARS-CoV antibody A 636 highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-637 A neutralizing human antibody binds to the N-terminal domain of the Spike 641 protein of SARS-CoV-2 Monoclonal antibodies 644 for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2 Fab-dimerized glycan-reactive antibodies are 654 a structural category of natural antibodies Neutralizing Antibodies for COVID-19 Prevention and Treatment Structural basis of SARS-659 CoV-2 and SARS-CoV-antibody interactions Neutralizing and 663 protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 664 spike protein Potent SARS-CoV-2 neutralizing 668 antibodies directed against spike N-terminal domain target a single supersite N-terminal domain antigenic mapping 675 reveals a site of vulnerability for SARS-CoV-2 Immunogenicity and 679 structures of a rationally designed prefusion MERS-CoV spike antigen Unexpected 683 Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion A 696 thermostable, closed SARS-CoV-2 spike protein trimer Mutations in or near 698 the fusion peptide of the influenza virus hemagglutinin affect an antigenic site in the globular 699 region Conformational changes in the Ebola virus membrane fusion machine induced by pH Ca2+, and receptor binding SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of 710 concern In 714 situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges Structures and distributions of SARS-CoV-2 spike proteins on 719 intact virions Monoclonal Antibodies Targeting the HR2 Domain and the Region Immediately 723 Upstream of the HR2 of the S Protein Neutralize In Vitro Infection of Severe Acute Respiratory 724 Syndrome Coronavirus Isolation and characterization of cross-neutralizing coronavirus 730 antibodies from COVID-19+ subjects Immunotherapeutic strategies to target vulnerabilities in the 732 Ebolavirus glycoprotein Ultrapotent human antibodies protect against SARS-CoV-2 challenge 740 via multiple mechanisms SARS-CoV-2 749 RBD antibodies that maximize breadth and resistance to escape Human Monoclonal Antibody Combination 753 against SARS Coronavirus: Synergy and Coverage of Escape Mutants The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose 757 Residues on the Outer Face of gp120 Gene splicing and mutagenesis by PCR-driven overlap 759 extension Direct 763 Visualization of the Conformational Dynamics of Single Influenza Hemagglutinin Trimers Conformational changes in the Ebola virus membrane fusion machine induced by pH Ca2+, and receptor binding Advanced 769 methods of microscope control using μManager software Single-molecule imaging of non-equilibrium molecular ensembles on the millisecond 772 timescale A Direct Optimization Approach to Hidden Markov Modeling 774 for Single Channel Kinetics Quantifying Interactions of β-Synuclein and γ-Synuclein with 776 Model Membranes Fluorescence correlation spectroscopy Correlation Coefficients: Appropriate Use and 779 Interpretation The authors thank Dr. Natasha Durham displayed as in (C) and (D). Numeric data are shown in Table S3 .